Nightly oral administration of topiramate for benign childhood epilepsy with centrotemporal spikes.

Abstract

OBJECTIVE:

The objective of this study was to explore the feasibility of nightly oral administration of topiramate for treating benign childhood epilepsy with centrotemporal spikes (BECTS).

METHODS:

Eighty-five children with BECTS receiving topiramate treatment were randomly divided into A group (44 patients) and B group (41 patients). In A group, topiramate was orally administrated once a night, with a final dose of 2 mg/kg/day. In B group, topiramate was orally administrated twice a day, with a final dose of 4 mg/kg/day. At the end of the 12-month follow-up period, clinical efficacy, changes in electroencephalographic (EEG) activity, and adverse reactions were analyzed.

RESULTS:

There was no significant difference in overall efficacy rate, percentages of patients achieving seizure free, or changes in EEG activity between the two groups (P > 0.05). The rate of adverse reactions for A group was 9.1 %, which was significantly lower than the 29.3 % for B group (χ (2) = 4.262, P < 0.05).

CONCLUSION:

Nightly oral administration of topiramate is a feasible strategy for the treatment of BECTS, with the advantages of comparable efficacy, convenience, and fewer adverse reactions.

• Authors: Chunrong Liu, Mei Song, Jiwen Wang
• Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (Childs Nerv Syst) Vol. 32 Issue 5 Pg. 839-43 (May 2016) ISSN: 1433-0350 [Electronic] Germany
• PMID: 26984807 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anticonvulsants
• Topiramate
• Fructose

Topics

• Administration, Oral
• Adolescent
• Anticonvulsants (administration & dosage, therapeutic use)
• Brain (physiopathology)
• Child
• Child, Preschool
• Drug Administration Schedule
• Electroencephalography
• Epilepsy, Rolandic (drug therapy, physiopathology)
• Female
• Fructose (administration & dosage, analogs & derivatives, therapeutic use)
• Humans
• Male
• Topiramate
• Treatment Outcome